Novartis set for 'clear win' in heart failure
This article was originally published in Scrip
Executive Summary
With a $10bn market potential on offer for each new effective heart failure drug, and Novartis and Bayer spearheading new research in the field, Deutsche Bank analysts have put out a new report which states that this vast potential could expand even further under certain positive scenarios through the concomitant use of therapies to treat different facets of the disease.